Zahed Subhan

Experience

1. Co-founder, Director

   Aestas Pharma Inc

   Dec 2015 — Present · NC, US

   Aestas Pharma Inc. is a pioneering biopharmaceutical company dedicated to the development of novel and diagnostic imaging and therapeutic agents to enable the early detection and reversal of severely debilitating Alzheimer’s diseases (AD) and Parkinson’s disease (PD). In marked contrast to competitor approaches, including current development stage drugs, Aestas is focused on targeting the very earliest stages of AD and PD, when clinical signs are not yet pronounced. Importantly, the company’s disease modifying AD therapeutic candidate may be combined with a biomarker for the early detection of AD pathology, in advance of significant plaque formation or neuronal loss. The company’s lead candidate, an \"aberrant\" Cdk5 PET imaging agent (AP-251) is expected to provide a first in class PET imaging tool for the early detection of AD/PD pathology, in advance of significant plaque formation or neuronal loss.

Education

• University of London

  LLB (Honors)

  1991 — 1994

• University of Sunderland

  BS (Honors)

  1976 — 1979

• Aston University, UK

  MS

  1979 — 1980

• University of Leeds

  PhD

  1980 — 1985

• Bradford University School of Management, UK

  MBA

  1985 — 1988